Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07824583
Recruiting Not applicable

A Study Evaluating a New Radiation Treatment Workflow (NGDS)

NCT07824583 · tracked via the Priya Life Science USA tracker
Sponsor
Varian, a Siemens Healthineers Company
Phase
Not applicable
Started
2026-07-31
Last updated
2026-09-17

Condition(s) studied

Lung Cancer (Diagnosis)Liver Cancer, AdultPancreatic CancerThoracic CancersAbdominal Cancer

Investigational drug(s) / intervention(s)

Next Generation Delivery System (NGDS)

Next Generation Delivery System (NGDS): Participant will receive a "mock" treatment on the NGDS machine. Participant will complete experience questionnaires.

Study summary

The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with less breath holding.

Eligibility

Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Target lesions in the thorax or upper abdomen 2. Planned to undergo SBRT radiation treatment delivered on a conventional "C-arm" or ring gantry CBCT guided linear accelerator under breath hold conditions 3. ECOG performance status 0-1 4. At least 21 years of age 5. Able to sign informed consent Exclusion Criteria: 1. Participants enrolled in another clinical investigation the investigator believes to be in conflict with this clinical investigation. 2. Participants with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Primary outcome measure(s)

  • To evaluate the feasibility of the mock NGDS DMAT workflow under breath hold conditions. — From enrollment to end of "mock" treatment of last participant enrolled, assessed up to 6 months
    Feasibility of the mock NGDS DMAT treatment workflow under breath hold conditions will be confirmed following successful execution of each step: 1. Acquisition of an IDENTIFY-monitored breath hold kV HyperSight CBCT 2. Conduct verification imaging of shifts and breath hold position using kV fluoroscopy 3. Delivery of an investigator approved "mock" DMAT treatment plan

Trial sites (2)

FacilityCityRegionStatus
Siteman Cancer Center Washington University St Louis Missouri Recruiting
University Hospital Cleveland Medical Center Cleveland Ohio Recruiting

More Varian, a Siemens Healthineers Company trials in the USA

Evaluation of Improved Onboard Patient Imaging Active, not recruiting
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT) Recruiting
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach Recruiting
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System Active, not recruiting
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix Recruiting

Other trials for the same condition

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Active, not recruiting
IDOV-Immune for Advanced Solid Tumors Recruiting
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations Active, not recruiting
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression Active, not recruiting
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07824583 on ClinicalTrials.gov ↗ ← All trials in the USA